

# Jogeshwar Mukherjee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9579505/publications.pdf>

Version: 2024-02-01

133  
papers

4,402  
citations

136950

32  
h-index

123424

61  
g-index

138  
all docs

138  
docs citations

138  
times ranked

4939  
citing authors

#	ARTICLE	IF	CITATIONS
1	Striatal Dopamine D <sub>2</sub> /D <sub>3</sub> Receptor Availability Is Reduced in Methamphetamine Dependence and Is Linked to Impulsivity. <i>Journal of Neuroscience</i> , 2009, 29, 14734-14740.	3.6	330
2	Brain imaging of 18F-fallypride in normal volunteers: Blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. <i>Synapse</i> , 2002, 46, 170-188.	1.2	260
3	11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas. <i>Molecular Imaging and Biology</i> , 2008, 10, 1-18.	2.6	210
4	Fluorinated benzamide neuroleptics—III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2,3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. <i>Nuclear Medicine and Biology</i> , 1995, 22, 283-296.	0.6	206
5	2-deoxy-2-[18F]fluoro-d-mannose positron emission tomography imaging in atherosclerosis. <i>Nature Medicine</i> , 2014, 20, 215-219.	30.7	159
6	Performance evaluation of an Inveon PET preclinical scanner. <i>Physics in Medicine and Biology</i> , 2009, 54, 2885-2899.	3.0	150
7	Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: In vivo imaging with [ <sup>18</sup> F]fallypride. <i>Movement Disorders</i> , 2010, 25, 2777-2784.	3.9	136
8	D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. <i>Schizophrenia Research</i> , 2006, 85, 232-244.	2.0	128
9	The Multiple Faces of Valosin-Containing Protein-Associated Diseases: Inclusion Body Myopathy with Paget's Disease of Bone, Frontotemporal Dementia, and Amyotrophic Lateral Sclerosis. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 522-531.	2.3	126
10	Preliminary assessment of extrastriatal dopamine d-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. <i>Nuclear Medicine and Biology</i> , 1999, 26, 519-527.	0.6	119
11	VCP Associated Inclusion Body Myopathy and Paget Disease of Bone Knock-In Mouse Model Exhibits Tissue Pathology Typical of Human Disease. <i>PLoS ONE</i> , 2010, 5, e13183.	2.5	109
12	Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, 18F-fallypride in nonhuman primates using positron emission tomography. <i>Synapse</i> , 1997, 27, 1-13.	1.2	76
13	Quantitative assessment of brown adipose tissue metabolic activity and volume using 18F-FDG PET/CT and β3-adrenergic receptor activation. <i>EJNMMI Research</i> , 2011, 1, 30.	2.5	73
14	Quantitation of striatal and extrastriatal D-2 dopamine receptors using PET imaging of [18F]fallypride in nonhuman primates. <i>Synapse</i> , 2000, 38, 71-79.	1.2	72
15	Evaluation of Dopamine D-2 Receptor Occupancy by Clozapine, Risperidone, and Haloperidol In Vivo in the Rodent and Nonhuman Primate Brain Using 18F-Fallypride. <i>Neuropsychopharmacology</i> , 2001, 25, 476-488.	5.4	71
16	Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E2239-48.	7.1	71
17	A progressive translational mouse model of human valosin-containing protein disease: The VCP <sup>R155H/+</sup> mouse. <i>Muscle and Nerve</i> , 2013, 47, 260-270.	2.2	58
18	Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET. <i>Brain Research</i> , 2005, 1032, 77-84.	2.2	57

#	ARTICLE	IF	CITATIONS
19	Adrenergic pathway activation enhances brown adipose tissue metabolism: A [ <sup>18</sup> F]FDG PET/CT study in mice. <i>Nuclear Medicine and Biology</i> , 2014, 41, 10-16.	0.6	57
20	Nicotinic $\alpha 4\beta 2$ receptor imaging agents. <i>Nuclear Medicine and Biology</i> , 2006, 33, 295-304.	0.6	56
21	The Homozygote VCP/R155H Mouse Model Exhibits Accelerated Human VCP-Associated Disease Pathology. <i>PLoS ONE</i> , 2012, 7, e46308.	2.5	56
22	Measuring the in Vivo Binding Parameters of [ <sup>18</sup> F]-Fallypride in Monkeys Using a PET Multiple-Injection Protocol. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004, 24, 309-322.	4.3	54
23	Synthesis and biologic evaluation of a novel serotonin 5-HT <sub>1A</sub> receptor radioligand, <sup>18</sup> F-labeled mefway, in rodents and imaging by PET in a nonhuman primate. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1697-706.	5.0	54
24	High-Affinity Dopamine D <sub>2</sub> /D <sub>3</sub> PET Radioligands <sup>18</sup> F-Fallypride and <sup>11</sup> C-FLB457: A Comparison of Kinetics in Extrastriatal Regions Using a Multiple-Injection Protocol. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 994-1007.	4.3	52
25	Image reconstruction for dynamic PET based on low-order approximation and restoration of the sinogram. <i>IEEE Transactions on Medical Imaging</i> , 1997, 16, 738-749.	8.9	49
26	Moderate-Level Prenatal Alcohol Exposure Alters Striatal Dopamine System Function in Rhesus Monkeys. <i>Alcoholism: Clinical and Experimental Research</i> , 2005, 29, 1685-1697.	2.4	45
27	Prenatal stress, moderate fetal alcohol, and dopamine system function in rhesus monkeys. <i>Neurotoxicology and Teratology</i> , 2004, 26, 169-178.	2.4	44
28	<sup>18</sup> F-desmethoxyfallypride: A fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for pet imaging studies of dopamine D <sub>2</sub> receptors. <i>Life Sciences</i> , 1996, 59, 669-678.	4.3	41
29	Evaluation of the binding of the radiolabeled antidepressant drug, <sup>18</sup> F-fluoxetine in the rodent brain: an in vitro and in vivo study. <i>Nuclear Medicine and Biology</i> , 1998, 25, 605-610.	0.6	38
30	Kinetics and mechanism of the oxidation of primary alcohols by N-bromoacetamide in acid medium. <i>Journal of Organic Chemistry</i> , 1981, 46, 2323-2326.	3.2	37
31	In vivo kinetics of [ <sup>18</sup> F]MEFWAY: A comparison with [ <sup>11</sup> C]WAY100635 and [ <sup>18</sup> F]MPPF in the nonhuman primate. <i>Synapse</i> , 2011, 65, 592-600.	1.2	36
32	Radiosynthesis of [ <sup>18</sup> F]fluoxetine as a potential radiotracer for serotonin reuptake sites. <i>Applied Radiation and Isotopes</i> , 1993, 44, 835-842.	1.5	34
33	Striatal and extrastriatal microPET imaging of D <sub>2</sub> /D <sub>3</sub> dopamine receptors in rat brain with [ <sup>18</sup> F]fallypride and [ <sup>18</sup> F]desmethoxyfallypride. <i>Synapse</i> , 2011, 65, 778-787.	1.2	33
34	Specific $\alpha 4\beta 2$ nicotinic acetylcholine receptor binding of [ <sup>18</sup> F]nifene in the rhesus monkey. <i>Synapse</i> , 2011, 65, 1309-1318.	1.2	33
35	Monoamine oxidase a inhibition by fluoxetine: An in vitro and in vivo study. , 1999, 31, 285-289.		32
36	<sup>11</sup> C-Fallypride: radiosynthesis and preliminary evaluation of a novel dopamine D <sub>2</sub> /D <sub>3</sub> receptor PET radiotracer in non-human primate brain. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 95-102.	3.0	31

#	ARTICLE	IF	CITATIONS
37	Nicotinic acetylcholine receptors in rat forebrain that bind <sup>18</sup> F-nifene: Relating PET imaging, autoradiography, and behavior. <i>Synapse</i> , 2012, 66, 418-434.	1.2	31
38	Effect of acetylcholinesterase inhibitors on the binding of nicotinic $\alpha 4\beta 2$ receptor PET radiotracer, <sup>18</sup> F-nifene: A measure of acetylcholine competition. <i>Synapse</i> , 2007, 61, 29-36.	1.2	28
39	Classification of Therapeutic and Experimental Drugs for Brown Adipose Tissue Activation: Potential Treatment Strategies for Diabetes and Obesity. <i>Current Diabetes Reviews</i> , 2016, 12, 414-428.	1.3	28
40	Radiobrominated m-tyrosine analog as potential CNS L-dopa pet tracer. <i>Biochemical and Biophysical Research Communications</i> , 1988, 150, 1027-1031.	2.1	27
41	Functional imaging of a large demyelinating lesion. <i>Journal of Clinical Neuroscience</i> , 2005, 12, 176-178.	1.5	27
42	PET Imaging of $\alpha 4\beta 2$ * Nicotinic Acetylcholine Receptors: Quantitative Analysis of <sup>18</sup> F-Nifene Kinetics in the Nonhuman Primate. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1471-1480.	5.0	26
43	Human brain imaging of nicotinic acetylcholine $\alpha 4\beta 2$ * receptors using [ <sup>18</sup> F]Nifene: Selectivity, functional activity, toxicity, aging effects, gender effects, and extrathalamic pathways. <i>Journal of Comparative Neurology</i> , 2018, 526, 80-95.	1.6	26
44	A Comparative Study on the Uptake and Incorporation of Radiolabeled Methionine, Choline and Fluorodeoxyglucose in Human Astrocytoma. <i>Molecular Imaging and Biology</i> , 2002, 4, 147-156.	2.6	25
45	Synthesis and biological evaluation of the binding of dopamine D2/D3 receptor agonist,		

#	ARTICLE	IF	CITATIONS
55	Binding characteristics of high-affinity dopamine D2/D3 receptor agonists, 11C-PPHT and 11C-ZYY-339 in rodents and imaging in non-human primates by PET. <i>Synapse</i> , 2004, 54, 83-91.	1.2	21
56	Evaluation of serotonin 5-HT <sub>1A</sub> receptors in rodent models using [ <sup>18</sup> F]mefway PET. <i>Synapse</i> , 2013, 67, 596-608.	1.2	21
57	Synthesis, radiosynthesis, and biological evaluation of fluorinated thienylcyclohexyl piperidine derivatives as potential radiotracers for the NMDA receptor-linked calcium ionophore. <i>Nuclear Medicine and Biology</i> , 1996, 23, 315-324.	0.6	20
58	[ <sup>18</sup> F]-Fallypride PET of Pancreatic Islets: In Vitro and In Vivo Rodent Studies. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1125-1132.	5.0	20
59	Evaluation of [ <sup>18</sup> F]Mefway Biodistribution and Dosimetry Based on Whole-Body PET Imaging of Mice. <i>Molecular Imaging and Biology</i> , 2013, 15, 222-229.	2.6	20
60	D <sub>2</sub> receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. <i>CNS Spectrums</i> , 2014, 19, 176-181.	1.2	20
61	First-in-Human Evaluation of [ <sup>18</sup> F]-Mefway, a PET Radioligand Specific to Serotonin-1A Receptors. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1973-1979.	5.0	19
62	Evaluation of monoamine oxidase B inhibition by fluoxetine (Prozac): An in vitro and in vivo study. <i>European Journal of Pharmacology</i> , 1997, 337, 111-114.	3.5	18
63	In vitro and in vivo evaluation of the binding of the dopamine D2 receptor agonist 11C-(R,S)-5-hydroxy-2-(di-n-propylamino)tetralin in rodents and nonhuman primate. , 2000, 37, 64-70.		18
64	N-(6- <sup>18</sup> F-Fluorohexyl)-N-Methylpropargylamine: A Fluorine-18-Labeled Monoamine Oxidase B Inhibitor for Potential Use in PET Studies. <i>Nuclear Medicine and Biology</i> , 1999, 26, 111-116.	0.6	17
65	Enhancement of [ <sup>18</sup> F]-fluorodeoxyglucose metabolism in rat brain frontal cortex using a <sup>123</sup> I-adrenoceptor agonist. <i>Synapse</i> , 2015, 69, 96-98.	1.2	17
66	Radiosynthesis and in vitro evaluation of 2-(N-alkyl-N- <sup>11</sup> C-propyl)amino-5-hydroxytetralin analogs as high affinity agonists for dopamine D-2 receptors. <i>Nuclear Medicine and Biology</i> , 1999, 26, 725-735.	0.6	16
67	An in vivo comparison of cis- and trans-[ <sup>18</sup> F]mefway in the nonhuman primate. <i>Nuclear Medicine and Biology</i> , 2011, 38, 925-932.	0.6	16
68	Measuring <sup>123</sup> I-α-BGT-944—Nicotinic Acetylcholine Receptor Density in Vivo with [ <sup>18</sup> F]nifene PET in the Nonhuman Primate. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1806-1814.	4.3	15
69	Preliminary evaluation of <sup>123</sup> I-adrenoceptor agonist-induced <sup>18</sup> F-FDG metabolic activity of brown adipose tissue in obese Zucker rat. <i>Nuclear Medicine and Biology</i> , 2015, 42, 691-694.	0.6	15
70	Comparative assessment of [ <sup>18</sup> F]-Mefway as a serotonin 5-HT <sub>1A</sub> receptor PET imaging agent across species: Rodents, nonhuman primates, and humans. <i>Journal of Comparative Neurology</i> , 2016, 524, 1457-1471.	1.6	15
71	Nicotinic <sup>123</sup> I-α-BGT-944 receptor imaging agents. Part III. Synthesis and biological evaluation of 3-(2-(S)-azetidinylmethoxy)-5-(3- <sup>18</sup> F-fluoropropyl)pyridine (18F-nifzetidine). <i>Nuclear Medicine and Biology</i> , 2011, 38, 1183-1192.	0.6	14
72	Measurement of 5-HT <sub>1A</sub> Receptor Density and <i>in-vivo</i> Binding Parameters of [ <sup>18</sup> F]mefway in the Nonhuman Primate. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1546-1558.	4.3	14

#	ARTICLE	IF	CITATIONS
73	D2/D3 dopamine receptor binding with [F-18]fallypride correlates of executive function in medication-naïve patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 192, 442-456.	2.0	14
74	Positive association between cerebral grey matter metabolism and dopamine D <sub>2</sub> /D <sub>3</sub> receptor availability in healthy and schizophrenia subjects: An <sup>18</sup> F-fluorodeoxyglucose and <sup>18</sup> F-fallypride positron emission tomography study. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 368-382.	2.6	14
75	[18F]Nifene PET/CT Imaging in Mice: Improved Methods and Preliminary Studies of $\alpha$ 4 $\beta$ 2* Nicotinic Acetylcholinergic Receptors in Transgenic A53T Mouse Model of $\alpha$ -Synucleinopathy and Post-Mortem Human Parkinson's Disease. <i>Molecules</i> , 2021, 26, 7360.	3.8	14
76	Nitrogen-15 NMR studies of the complex of carbonic anhydrase with the novel carbonyl hydration substrate pyruvamide. Evidence for the coordination of the deprotonated amide group to the active site zinc. <i>Journal of the American Chemical Society</i> , 1987, 109, 7232-7233.	13.7	13
77	Nicotinic $\alpha$ 4 $\beta$ 2 receptor imaging agents. Part IV. Synthesis and Biological Evaluation of 3-(2-(S)-3,4-dehydropyrrolinyl methoxy)-5-(3- <sup>18</sup> F-fluoropropyl)pyridine (18F-Nifrolene) using PET. <i>Nuclear Medicine and Biology</i> , 2013, 40, 117-125.	0.6	13
78	[ <sup>18</sup> F]Nifene test-retest reproducibility in first-in-human imaging of $\alpha$ 4 $\beta$ 2* nicotinic acetylcholine receptors. <i>Synapse</i> , 2017, 71, e21981.	1.2	13
79	Fluorinated benzamide neuroleptics <sup>2</sup> . Synthesis and radiosynthesis of (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(3-[ <sup>18</sup> F]fluoropropyl)-3-substituted-2-methoxybenzamides. <i>International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes</i> , 1991, 42, 713-721.	0.5	12
80	Positron autoradiography for intravascular imaging: feasibility evaluation. <i>Physics in Medicine and Biology</i> , 2006, 51, 963-979.	3.0	12
81	Imaging Pancreas in Healthy and Diabetic Rodent Model Using [ <sup>18</sup> F]Fallypride Positron Emission Tomography/Computed Tomography. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 640-643.	4.4	12
82	124I-Epididride: A PET radiotracer for extended imaging of dopamine D2/D3 receptors. <i>Nuclear Medicine and Biology</i> , 2014, 41, 426-431.	0.6	12
83	Evaluation of [ <sup>11</sup> C]TAZA for amyloid $\beta$ 2 plaque imaging in postmortem human Alzheimer's disease brain region and whole body distribution in rodent PET/CT. <i>Synapse</i> , 2016, 70, 163-176.	1.2	12
84	[18F]FDG PET/CT Studies in Transgenic H $\alpha$ lpha-Syn (A53T) Parkinson's Disease Mouse Model of $\alpha$ -Synucleinopathy. <i>Frontiers in Neuroscience</i> , 2021, 15, 676257.	2.8	12
85	Interaction of the unique competitive inhibitor imidazole and related compounds with the active site metal of carbonic anhydrase: linkage between pH effects on the inhibitor binding affinity and pH effects on the visible spectra of inhibitor complexes with the cobalt-substituted enzyme. <i>Biochemistry</i> , 1987, 26, 7057-7063.	2.5	11
86	Fluorinated benzamide neuroleptics. 1. Radiosynthesis of (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(2-[F-18]fluoroethyl)-2-methoxybenzamide: A potential fluorine-18 labeled PET radiotracer for dopamine D2 receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1990, 28, 609-616.	1.0	11
87	Development of N-[3-(2,4-dichlorophenoxy)-2- <sup>18</sup> F-fluoropropyl]-N-methylpropargylamine (18F-fluorocloglyline) as a potential PET radiotracer for monoamine oxidase-A. <i>Nuclear Medicine and Biology</i> , 1999, 26, 619-625.	0.6	11
88	The effects of lobeline on $\alpha$ 4 $\beta$ 2* nicotinic acetylcholine receptor binding and uptake of [18F]nifene in rats. <i>Journal of Neuroscience Methods</i> , 2013, 214, 163-169.	2.5	11
89	PET imaging of acetylcholinesterase inhibitor-induced effects on $\alpha$ 4 $\beta$ 2 nicotinic acetylcholine receptor binding. <i>Synapse</i> , 2013, 67, 882-886.	1.2	11
90	<sup>18</sup> F-Fluorodeoxyglycosylamines: Maillard reaction of <sup>18</sup> F-fluorodeoxyglucose with biological amines. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 86-91.	1.0	11

#	ARTICLE	IF	CITATIONS
91	Multimodality Imaging Probe for Positron Emission Tomography and Fluorescence Imaging Studies. <i>Molecular Imaging</i> , 2014, 13, 7290.2014.00005.	1.4	11
92	Human biodistribution and dosimetry of [ <sup>18</sup> F]nifene, an $\alpha_4\beta_2$ nicotinic acetylcholine receptor PET tracer. <i>Nuclear Medicine and Biology</i> , 2017, 55, 7-11.	0.6	11
93	Dopamine receptor density and white matter integrity: 18F-fallypride positron emission tomography and diffusion tensor imaging study in healthy and schizophrenia subjects. <i>Brain Imaging and Behavior</i> , 2020, 14, 736-752.	2.1	11
94	Development and evaluation of [ <sup>18</sup> F]Flotaza for $\alpha_2$ plaque imaging in postmortem human Alzheimer's disease brain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 46, 128164.	2.2	11
95	[ <sup>124</sup> I]IBETA: A New $\alpha_2$ Plaque Positron Emission Tomography Imaging Agent for Alzheimer's Disease. <i>Molecules</i> , 2022, 27, 4552.	3.8	11
96	Use of Diethylaminosulfur Trifluoride in an Efficient Synthesis of		

#	ARTICLE	IF	CITATIONS
109	Synthesis of radiobrominated m-tyrosine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1989, 27, 189-194.	1.0	6
110	Development of fluorescence imaging probes for nicotinic acetylcholine $\alpha_7$ receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 371-377.	2.2	6
111	Radiotracers for a multi-target approach to the diagnosis of Alzheimer's disease. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2007, 50, 375-379.	1.0	5
112	Ketoconazole-Associated Preferential Increase in Dopamine D2 Receptor Occupancy in Striatum Compared to Pituitary In Vivo. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 110-113.	1.4	5
113	Targeting histone deacetylase in lung cancer for early diagnosis: (18)F-FAHA PET/CT imaging of NNK-treated A/J mice model. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 324-32.	1.0	5
114	Comparison of the interaction of dopamine and high affinity positron emission tomography radiotracer fallypride with the dopamine D-2 receptor: a molecular modeling study. <i>Journal of Molecular Modeling</i> , 2001, 7, 6-18.	1.8	4
115	PET radiotracer development for imaging high-affinity state of dopamine D2 and D3 receptors: Binding studies of fluorine-18 labeled aminotetralins in rodents. <i>Synapse</i> , 2017, 71, e21950.	1.2	4
116	Reading abilities and dopamine D2/D3 receptor availability: An inverted U-shaped association in subjects with schizophrenia. <i>Brain and Language</i> , 2021, 223, 105046.	1.6	4
117	Synthesis and evaluation of 2-(18)F-fluoro-5-iodo-3-[2-(S)-3,4-dehydropyrrolinylmethoxy]pyridine ((18)F-Niofene) as a potential imaging agent for nicotinic $\alpha_7$ receptors. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 354-64.	1.0	4
118	Multimodality imaging probe for positron emission tomography and fluorescence imaging studies. <i>Molecular Imaging</i> , 2014, 13, 1-7.	1.4	4
119	Kinetics and mechanism of the oxidation of substituted benzyl alcohols by sodium N-chlorobenzenesulphonamide. <i>Journal of the Chemical Society Perkin Transactions II</i> , 1980, , 676.	0.9	3
120	18F-Fluorodeoxyglucamines: Reductive amination of hydrophilic 18F-fluoro-2-deoxyglucose with lipophilic amines for the development of potential PET imaging agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2902-2906.	2.2	3
121	Fluorine-18 labelled substituted benzazepines as potential radiotracers for imaging dopamine D1 receptors by positron emission tomography. <i>European Journal of Pharmacology</i> , 1993, 243, 287-290.	3.5	2
122	Initial in vivo PET imaging of 5-HT1A receptors with 3-[(18)F]mefway. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 483-9.	1.0	2
123	( <sup>18</sup> F)-MFP3 as a potential PET imaging agent for norepinephrine transporter. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2010, 53, 172-177.	1.0	1
124	Synthesis and evaluation of mefway analogs as ligands for serotonin 5HT1A receptors. <i>Medicinal Chemistry Research</i> , 2015, 24, 1480-1486.	2.4	1
125	79. D2/D3 Dopamine Receptor Binding With [F-18] Fallypride Correlates of Executive Function in Medication-Naive Patients With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2017, 43, S44-S45.	4.3	1
126	Development of zirconium-89 PET for imaging of alpha-klotho. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 10, 95-105.	1.0	1



#	ARTICLE	IF	CITATIONS
127	Four-modality imaging of unmedicated subjects with schizophrenia: 18F-fluorodeoxyglucose and 18F-fallypride PET, diffusion tensor imaging, and MRI. <i>Psychiatry Research - Neuroimaging</i> , 2022, 320, 111428.	1.8	1
128	Radiopharmaceuticals for Imaging the Brain. , 2004, , 89-101.		0
129	Modulating Blood-Brain Barrier Permeability and Treatment-Resistant Psychiatric Illness: Is Pituitary Neuroimaging a New Frontier?. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2012, 10, 182-184.	0.2	0
130	Synthesis and biological evaluation of 18F-Norfallypride in the rodent brain using PET imaging. <i>Nuclear Medicine and Biology</i> , 2013, 40, 697-704.	0.6	0
131	283. D2/D3 Dopamine Receptor Binding with [F-18] Fallypride Correlates of Executive Function in Medication-Naïve Patients with Schizophrenia. <i>Biological Psychiatry</i> , 2017, 81, S116-S117.	1.3	0
132	Methodological development of dynamic dopamine release using [18F]desmethoxyfallypride. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S612-S612.	4.3	0
133	Development of Fluorine-18 Radiopharmaceuticals for Dopamine Neuroreceptors. , 1995, , 265-275.		0